n IntroductIon O steoporosis is defined as a skeletal disorder characterized by an impairment of the mechanical resistance of the bone, causing an increased risk of fracture. This resistance is mainly a combination of bone density and quality (1) . Therefore, a reduction in bone mass and microarchitecture results in fragile bones which fracture after light, that is low energy trauma. Fragile bone fractures are considered one of the major causes of morbidity and death worldwide (2), besides making a significant contribution to health care costs (3) . In Italy, each year over 80,000 fractures of the proximal end of the femur are registered as being due to osteoporosis, with a net prevalence (72%) in women (3) . A number of guidelines describe different combinations of therapeutic and diagnos-original article
Adherence to therapeutic and diagnostic recommendations tic procedures to improve the prognosis of patients with femur fracture, and to reduce the risk of re-fracture and death (4, 5) . These recommendations include the identification of subjects at high risk of re-fracture (e.g. patients with previous femur fracture), diagnostic, laboratory and instrumental tests, non-pharmacological measures of prevention and cure (e.g. calcium and vitamin D levels), indications for pharmacological treatment. In particular, these recommendations underline the importance of the diagnosis of osteoporosis by X-ray densitometry and analyze the contribution of multiple risk factors to the reduction of bone mass. Differential diagnosis of osteoporosis is extremely important, particularly in diseases with mechanisms which to a greater or lesser degree can increase the risk of fracture. It is important that the patient undergoes a clinical examination and a series of simple 1st level biochemical tests to exclude secondary osteoporosis. These should include calcemia, creatinine phosphate, calciuria, serum protein fractionation, and ESR. According to guidelines, densitometry screening is recommended for all women after the age of 65 years. In spite of these therapeutic and diagnostic guidelines, very little scientific evidence has been transferred into clinical practice, and this has important clinical (6-16) and economic (17) (18) (19) (20) (21) (22) implications. The aim of this study was to measure the degree of transfer into clinical practice of these therapeutic and diagnostic recommendations for the prevention of bone refracture in post-menopausal women with femur fracture. The study also aims to evaluate the level of association between these recommendations (from now on referred to, in general, as adherence to recommendations) and the risk of re-fracture or death.
n MaterIals and Methods
Data sources
Data of study subjects were extracted from the databases of five local health authorities (LHA) in five regions of Italy:
Lombardy, Emilia-Romagna, Tuscany, Campania and Calabria, with a total of two and a half million patients registered. In order to trace the assistance given, the local health authorities have various information flow systems for their local pharmaceutical services (LPS), direct pharmaceutical distribution (DPD), specialist visits (SV), hospital discharge records (HDR) and deaths. These systems allowed patients receiving these services to be traced. Using appropriate data linkage procedures, it is possible to create a population databank containing individual, analytical and chronological profiles of all patients registered with the LHA. These databanks are known as administrative databanks and their role in the analysis of pharmacological utilization has been confirmed in numerous previous studies (23) (24) (25) . In compliance with the laws on privacy, the patient's identity code was encrypted and those responsible for data management were not provided with any information which could lead to direct or indirect identification of the patient involved. The local ethics committees of all LHA participants were informed of the study according to the legal requirements concerning observational analysis. Because of the low numbers, adherence to treatment was not calculated in patients exposed to other drug treatments (parathyroid hormones and analogs, calcitonin based drugs, raloxifene). For those patients who died or were transferred to another LHA during the observation period, analysis of the drug treatment was carried out until the date of death or transfer.
Patients

Diagnostic tests
Study patients were classified as exposed or not exposed to diagnostic tests related to the bone fracture on the basis of the presence or absence of at least one prescrip- n results A total of 5,686 patients were selected for the study. Of these, 50 patients (0.8% of selected patients) were excluded because they had been admitted with a diagnosis of bone tumor, bone metastasis or pathological fracture. Average age of the remaining 5,636 patients was 82.7±7.3 years (range 65-103 years).
Drug treatment
Exposure to drug treatment for the fracture (previous to and/or subsequent to the fracture) was reported in 16.3% of patients. Of these, 28.9% also presented treatment previous to the femur fracture (Table I ). Just 4.6% of patients received only calcium or vitamin D supplements. Figure 1 shows the prevalence of the use of different drug treatments and calcium or vitamin D supplements in the period previous or subsequent to the femur fracture. Among patients exposed to drug treatment for bone fracture, 62.0% also received calcium or vitamin D supplements. Among those who, on the contrary, were not exposed to specific drug treatment, 17.5% received only calcium or vitamin D supplements (Table II) . (Table  III) . Of these last patients, 38 patients used bisphosphonates and and strontium ranelate. In this study, given the reduced number of patients with more than one treatment, the question as to whether this concerned treatment associated with others or substituting others was not explored (Table III (Table IV) .
Diagnostic tests
At least one 1st level laboratory test was prescribed in 53.7% of patients, at least one 1st level instrumental test in 43.1%,and at least one 2nd level instrumental test in 0.8% (Table V) . Table V shows the number of patients who were prescribed at least one diagnostic test in the period previous and/or subsequent to (Table VII) .
n dIscussIon
Results confirm that there is little transfer of diagnostic and therapeutic recommendations into clinical practice for the prevention of bone re-fracture in post- original article menopausal patients with femur fracture. With respect to most studies in this field, (13-15) the present analysis examined adherence to diagnostic recommendations and showed that far fewer 1st and 2nd level laboratory and instrumental tests were prescribed than are suggested in available guidelines (4, 5) . In particular, prescription of laboratory tests was low (53.7% and 43.1% of patients were prescribed, respectively, 1st and 2nd level tests) and very low for instrumental tests such as X-rays and densitometry (5.9% and 0.8% patients were prescribed, respectively, 1st and 2nd level tests). In addition, there was no increase in the number of patients who were prescribed a diagnostic test in the period after the fracture with respect to the period before the fracture (from 46.3 to 53.7% for 1st These results are in line with previous studies (13) (14) (15) (16) 22) and are important, above all, in this study cohort of patients who, having had a previous fracture event, are already at a particularly high risk of new fragile fracture. Adherence to treatment is a further problem. In fact, of the patients exposed, only a quarter had adequate therapeutic cover. The second important result from this study is the extent of the relationship between application of the therapeutic and diagnostic recommendations and the risk of re-fracture or death in post-menopausal patients with femur fracture. In accordance with previous studies, (6-12) treatment for osteoporosis was protective and had an impact, above all, on total mortality (-62.3% of risk with respect to patients not undergoing treatment). Calcium and vitamin D supplements were also protective (-31.8 and -39.3% of risk, respectively, of re-fracture and death, with respect to patients not receiving supplements). Besides drug treatment, the present study analyzed the effect of prescription of the recommended diagnostic tests. The prescription of 1st level instrumental tests such as X-rays (back, lumbosacral, and spine) and densitometry is associated with a -72.1% reduction in re-fracture risk and a -54.1% reduction in death risk (respect to patients who were not prescribed these tests). It would be quite reasonable to attribute this to an increased awareness of the real condition of the patient and to the appropriate therapeutic strategies which were consequently adopted.
The main limitation of this study was that some clinical information concerning patients was not available in the administrative information flow systems which are currently used. The most important information which was missing concerned the severity of osteoporosis.
Since in clinical practice the severity of osteoporosis is in itself a factor which increases the need for drug treatment and diagnostic tests, the socio-economic status, anthropometric parameters and, above all, the study of the relationship between adherence to therapeutic and diagnostic recommendations and the risk of re-fracture (in cases in which the severity of the osteoporosis was not recorded) could not explained why each individual parameter contributed to the risk of re-fracture or death. In particular, the lack of confirmation of a diagnosis of osteoporosis could have led to the inclusion of patients with traumatic and not osteoporotic fracture. However, selection criteria in the study cohort meant only female patients aged over 65 years were included and this should have minimized such a risk. Selection criteria with particular reference to previous femur fracture, should also have limited any possible bias in the therapeutic indications, since these patients, precisely because of the fracture event, were in any case exposed to a continuative preventive treatment (confounding by indication).
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